Nicole Onetto
Director/Board Member at BOLT BIOTHERAPEUTICS, INC.
Net worth: 31 741 $ as of 29/04/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
William Quinn | M | 53 | 7 years | |
Adesh Kaul | M | 50 | 15 years | |
Mark Rothera | M | 61 | 2 years | |
Domenico Scala | M | 59 | 13 years | |
Damian Heller | M | 58 | 9 years | |
Alf Gunnar Martin Nicklasson | M | 69 | 11 years | |
Melody Burcar | F | 41 | 2 years | |
Christian Leisner | M | - |
CDR-Life Inc.
CDR-Life Inc. BiotechnologyHealth Technology CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017. | 7 years |
Jane Chung | F | 53 | 2 years | |
Joseph J. Kenny | M | - | 15 years | |
Frank Lee | M | 56 | 3 years | |
David Veitch | M | 59 | 10 years | |
Marc Engelhardt | M | 60 | 14 years | |
Laura Berner | F | 49 | 2 years | |
Karen L. Bergman | F | - | - | |
Thomas Werner | M | 68 | 13 years | |
Mahendra Shah | M | 79 | 8 years | |
Sarah Nemec | F | 48 | 4 years | |
Richard Miller | M | 73 | 7 years | |
Ashleigh Barreto | F | - | 3 years | |
Peer Nils Schröder | M | - | - | |
Leonard Kruimer | M | 66 | 2 years | |
Sandra Leung | F | 63 | 32 years | |
Dominik Escher | M | - |
CDR-Life Inc.
CDR-Life Inc. BiotechnologyHealth Technology CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017. | 7 years |
James Healy | M | 59 | 3 years | |
Erich Schlick | M | 72 |
NBE-Therapeutics AG
NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | 4 years |
Kathy LaPorte | F | 62 | 4 years | |
Theresa Wingrove | M | 66 | 13 years | |
Grant Yonehiro | M | 60 | 8 years | |
Brian O'Callaghan | M | 54 | 3 years | |
John Tomaro | M | - | 4 years | |
Yu Tai | M | - | - | |
Dung Tran Ngoc | F | - | - | |
Daniel Marks | M | - |
CDR-Life Inc.
CDR-Life Inc. BiotechnologyHealth Technology CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017. | - |
Wesley Burwell | M | - | 3 years | |
Audrey Bergan | F | - | 10 years | |
Jeffrey Courtney | M | 65 |
Ontario Institute for Cancer Research
Ontario Institute for Cancer Research Hospital/Nursing ManagementHealth Services Ontario Institute for Cancer Research provides research on the prevention, early detection, diagnosis, and treatment of cancer. It offers Innovation programs, like cancer stem cell, innovation in target validation, and smarter imaging, Technology programs, like drug discovery, genome technologies, informatics and bio-computing, imaging translation, and tranformative pathology, and Translation programs. The company was founded by Calvin R. Stiller in December 2005 and is headquartered in Toronto, Canada. | 12 years |
Laurenz Kellenberger | M | 57 | 24 years | |
Priti Hegde | M | 52 | - | |
Gerrit Hauck | M | 60 | 6 years | |
Claudio Nessi | M | 56 |
CDR-Life Inc.
CDR-Life Inc. BiotechnologyHealth Technology CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017. | - |
Ursula Eberhardt | F | 62 | 18 years | |
Bertrand Damour | M | - |
NBE-Therapeutics AG
NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | 4 years |
Robert N. Klein | M | - |
Ontario Institute for Cancer Research
Ontario Institute for Cancer Research Hospital/Nursing ManagementHealth Services Ontario Institute for Cancer Research provides research on the prevention, early detection, diagnosis, and treatment of cancer. It offers Innovation programs, like cancer stem cell, innovation in target validation, and smarter imaging, Technology programs, like drug discovery, genome technologies, informatics and bio-computing, imaging translation, and tranformative pathology, and Translation programs. The company was founded by Calvin R. Stiller in December 2005 and is headquartered in Toronto, Canada. | 11 years |
Rafaèle Elisabeth Tordjman | M | 54 |
CDR-Life Inc.
CDR-Life Inc. BiotechnologyHealth Technology CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017. | - |
Stewart M. Brown | M | - | 2 years | |
Dawn Colburn | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Dayton Misfeldt | M | 50 | 11 years | |
David B. Johnston | M | 68 | 5 years | |
Mitchel Sayare | M | 76 | 25 years | |
Edgar Engleman | M | 78 | 9 years | |
Michael Atieh | M | 70 | 5 years | |
Mark Enyedy | M | 60 | 8 years | |
Robert E. Pelzer | M | 70 | 7 years | |
Achim Kaufhold | M | 66 | 7 years | |
Stephen McCluski | M | 72 | 17 years | |
Mark Goldberg | M | 69 | 13 years | |
Tran Nguyen | M | 50 | 3 years | |
Randall Schatzman | M | 69 | 5 years | |
James Sapirstein | M | 63 | 6 years | |
Andrew Sinclair | M | 52 | 3 years | |
Wendi V. Rodrigueza | M | 58 | 10 years | |
Michael Huang | M | 50 | 3 years | |
Hans-Peter Gerber | M | - |
NBE-Therapeutics AG
NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | 4 years |
Alvin Vitangcol | M | 49 | 3 years | |
Thomas Ryll | M | 64 | 6 years | |
Mona Ashiya | M | 55 | 3 years | |
Kristine Peterson | F | 64 | 12 years | |
Gabriel Fox | M | - |
NeXstar Pharmaceuticals, Inc.
NeXstar Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NeXstar Pharmaceuticals, Inc. was a commercial biopharmaceutical company engaged in the discovery, development, manufacture and marketing of proprietary pharmaceutical products to treat life-threatening and other serious diseases. The firm was located in Boulder, CO. | 4 years |
Daniel J. Estes | M | 43 | 2 years | |
Barbara Klencke | M | 66 | 7 years | |
James Smith | M | 54 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 3 years |
Elizabeth Rozek | F | 53 | 7 years | |
Sarah Kiely | F | - | 7 years | |
David Warren Carter | M | 84 | 14 years | |
Gaurav Aggarwal | M | 51 | 3 years | |
Suzanne M. Cadden | F | 64 | - | |
Laurie Glimcher | M | 72 | 20 years | |
Craig Barrows | M | 69 | 13 years | |
Charles Sigal | M | 72 | 16 years | |
Dean Mitchell | M | 68 | 12 years | |
Suzanne M. Shema | F | 66 |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | 8 years |
Anthony Hooper | M | 69 | 15 years | |
Lawrence Hamilton | M | 66 | 8 years | |
Jeffrey Cooper | M | 68 | 6 years | |
Steven Skolsky | M | 68 | 15 years | |
Andrew Allen | M | 57 | 5 years | |
Mark B. Skaletsky | M | 75 | 13 years | |
Richard Wallace | M | 72 | 17 years | |
Howard H. Pien | M | 66 | 9 years | |
Robert L. Simon | M | 79 | 1 years | |
Donald Parfet | M | 71 | 4 years | |
Patrick Mahaffy | M | 61 |
NeXstar Pharmaceuticals, Inc.
NeXstar Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NeXstar Pharmaceuticals, Inc. was a commercial biopharmaceutical company engaged in the discovery, development, manufacture and marketing of proprietary pharmaceutical products to treat life-threatening and other serious diseases. The firm was located in Boulder, CO. | 6 years |
Albert Cha | M | 51 | 2 years | |
James Topper | M | 62 | 3 years | |
Peter Thompson | M | 64 | 1 years | |
Gur Roshwalb | M | 55 | 1 years | |
Priya Jambhekar | F | - | 3 years | |
David Dornan | M | 46 | 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 72 | 72.73% |
Switzerland | 24 | 24.24% |
Canada | 2 | 2.02% |
United Kingdom | 1 | 1.01% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Nicole Onetto
- Personal Network